Skip to main content
Hana Pharm. Co., Ltd. logo

Hana Pharm. Co., Ltd. — Investor Relations & Filings

Ticker · 293480 ISIN · KR7293480000 KO Manufacturing
Open in API
Filings indexed 243 across all filing types
Latest filing 2022-03-21 Annual Report
Country KR South Korea
Listing KO 293480

About Hana Pharm. Co., Ltd.

http://www.hanaph.co.kr/eng/index.do

Hana Pharm. Co., Ltd. is a pharmaceutical company engaged in the development, manufacturing, and distribution of a wide range of medical products. The company specializes in anesthetics and narcotic analgesics, establishing a strong position in these therapeutic areas. Its portfolio also encompasses generic drugs, active pharmaceutical ingredients (APIs), antiemetics, and antibiotics. Focused on innovation, Hana Pharm's research and development pipeline includes novel drugs targeting the nervous system. Key projects under development are Byfavo Inj. (remimazolam), an ultra-short-acting anesthetic and sedative, and a new multi-functional MRI contrast agent. The company serves a global market and is expanding its capacity for injectable medicines to meet growing demand.

Recent filings

Filing Released Lang Actions
사업보고서 (2021.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for Hana Pharm Co., Ltd. for the fiscal year 2021 (January 1, 2021, to December 31, 2021). It contains comprehensive company information, financial data, business operations, and management details, which is the standard format for an Annual Report in the South Korean regulatory framework (DART). FY 2021
2022-03-21 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Hana Pharm Co., Ltd. It contains the meeting agenda, including financial statement approval, director appointments, and remuneration limits, as well as management reports and governance information. This type of document is standard for proxy solicitation and shareholder information, falling under the 'Proxy Solicitation & Information Statement' category.
2022-03-11 Korean
주주총회집중일개최사유신고
AGM Information Classification · 95% confidence The document is a formal regulatory filing submitted to the Korea Exchange (KRX) regarding the 'Reason for holding a General Meeting of Shareholders on a concentrated date'. It explains why the company (Hana Pharm) is holding its AGM on a date that coincides with other companies' meetings, citing scheduling conflicts. Since this is a specific regulatory disclosure regarding meeting logistics rather than the meeting materials themselves or a proxy statement, it falls under the general regulatory filing category.
2022-03-11 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Hana Pharm. It outlines the date, location, and agenda items (such as financial statement approval, director appointments, and remuneration limits) for the upcoming Annual General Meeting. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the meeting and request their votes, which aligns with the Proxy Solicitation & Information Statement (PSI) category.
2022-02-28 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from Hana Pharm regarding a decision on cash dividends. It specifies the dividend amount per share, the total dividend amount, the dividend record date, and the date of the upcoming general meeting of shareholders to approve the dividend. This fits the definition of a 'Notice of Dividend Amount' (DIV).
2022-02-28 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경
Earnings Release Classification · 100% confidence The document is a regulatory filing from Hana Pharm regarding a significant change in financial results (revenue/profit structure). It provides preliminary financial data for the fiscal year, explicitly stating it is based on internal accounting and subject to change upon final audit. This type of disclosure is a standard preliminary earnings announcement required by the Korea Exchange (KRX) when financial metrics shift by a certain percentage, fitting the definition of an Earnings Release (ER). FY 2021
2022-02-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.